Dr. Manuel Hidalgo Appointed Director and Scientific Advisor of Champions Biotechnology, Inc.
Arlington, VA – June 11, 2007 – Champions Biotechnology, Inc. (OTC Bulletin Board:CSBR), a development stage biotechnology company, announced the appointment of Dr. Manuel Hidalgo to serve as a Director on the Company’s Board of Directors and as a Scientific Advisor. In that capacity he will advise and assist the Company in the development of novel Benzoylphenylurea (BPU) sulfur analog compounds and the novel human cancer xenograft platform that the Company acquired recently. In addition, Dr. Hidalgo will advise the Company on future therapeutic drug candidates and technologies that the Company intends to acquire. He will also assist the Company in the formation of its Scientific Advisory Board.
Dr. Manuel Hidalgo, M.D., Ph.D., is the Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine and Director of the Centro Integral Oncologia “Clara Campal” in Madrid, Spain. He is considered a leading researcher in the field of targeted therapies for the treatment of cancer in patients with solid tumors.
His research interest focuses on the development of novel anticancer agents for patients with gastrointestinal cancer by measuring target receptor and molecular anomalies, as well as analyzing biological activity in the tumor and normal tissues of patients treated with specific therapies. Dr. Hidalgo’s laboratory has been involved in the development of the Champions Biotechnology’s BPU sulfur analog compounds, published recently in theAmerican Association for Cancer Research
Journal of Molecular Cancer Therapeutics, Vol. 6, Issue 5, May 2007, 1509-16.
“The Company is very excited to have such a recognized leader in the field agree to join its Board of Directors and also become the Scientific Advisor.” said James Martell, Chairman, President and CEO of Champions Biotechnology. “Dr. Hidalgo’s combination of clinical and research expertise and contacts in industry and government will be invaluable to the Company as we begin our growth as a biotechnology company.”
Dr. Hidalgo has published over 140 papers in prestigious cancer journals as well as numerous chapters in important text books. He has received numerous awards including an AACR Young Investigator Award, an NCI-EORTC fellowship and an ASCO Career Development Award.
He has served on the editorial board of the Journal of Clinical Oncology and Clinical Cancer Research and is a Senior Editor for Molecular Cancer Therapeutics. Dr. Hidalgo has chaired the AACR and ASCO Program Committee in developmental therapeutics on numerous occasions and is frequently invited to speak at major national and international meetings. He chairs the Pancreatic Cancer Research Team, a nonprofit organization focused on clinical trials in pancreatic cancer and is also a member of the NCI Developmental Therapeutics Study Section.